Get the Stockscreener App
0.9807
0.79%
0.0077
Pds Biotechnology Corp stock is traded at $0.9807, with a volume of 284.59K.
It is up +0.79% in the last 24 hours and up +61.75% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
See More
Previous Close:
$0.973
Open:
$1
24h Volume:
284.59K
Relative Volume:
0.39
Market Cap:
$54.74M
Revenue:
-
Net Income/Loss:
$-34.50M
P/E Ratio:
-1.3116
EPS:
-0.7477
Net Cash Flow:
$-27.75M
1W Performance:
+8.91%
1M Performance:
+61.75%
6M Performance:
+4.88%
1Y Performance:
-26.26%
1-Day Range:
$0.963
$1.02
1-Week Range:
$0.88
$1.16
52-Week Range:
$0.5068
$1.915
Pds Biotechnology Corp Stock (PDSB) Company Profile
Name
Pds Biotechnology Corp
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
0.9807 | 54.74M | 0 | -34.50M | -27.75M | -0.7477 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corp Stock (PDSB) Latest News
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April - MarketBeat
[EFFECT] PDS Biotechnology Corp SEC Filing - Stock Titan
PDS Biotech 2025 Executive Compensation, Leadership Structure, and Equity Ownership Overview - Minichart
[10-K/A] PDS Biotechnology Corp Amends Annual Report - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) registers $200M shelf, removes $20M ATM - Stock Titan
PDS Biotechnology: FDA-Alignment für VERSATILE-003 - Börse Global
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts - TradingView
PDS Biotech (NASDAQ: PDSB) spotlights PDS0101 Phase 3 and IL-12 ADC - Stock Titan
PDS (PDSB) Stock Analysis: Buy or Sell? | PDS Biotechnology Corporation posts 24.4% EPS beatConsensus Forecast - Cổng thông tin điện tử tỉnh Lào Cai
Form DEF 14AOther definitive proxy statements - ADVFN
PDSB: Positive Data from Phase 2 Trial of PDS01ADC Published - GuruFocus
PDSB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15.00 - GuruFocus
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - MarketBeat
Why Is PDS Biotechnology Stock Gaining Wednesday?PDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotech’s PDS01ADC Shows 78% Response Rate in Phase 2 Metastatic Colorectal Cancer Trial, Published in JCO Oncology Advances - Minichart
PDS Biotech reports 78% response rate in colorectal cancer trial - Investing.com
PDS Biotech reports 78% response rate in colorectal cancer trial By Investing.com - Investing.com South Africa
Interim PDS01ADC data lift responses in tough mCRC for PDS Biotech (PDSB) - Stock Titan
PDS Biotechnology Announces Promising Phase 2 Trial Results of PDS01ADC for Treatment of Colorectal Liver Metastases - Quiver Quantitative
In a 9-patient colon cancer study, PDS drug showed 78% response - Stock Titan
Aug Drivers: Is PDS Biotechnology Corporation trading at a discount2026 Earnings Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Is PDS (PDSB) Stock Expanding | Price at $1.09, Up 0.93%Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Is PDS (PDSB) Stock Declining | Price at $0.76, Up 19.06%Retail Trader Ideas - Xã Vĩnh Công
What is HC Wainwright’s Estimate for PDSB FY2026 Earnings? - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript - Insider Monkey
PDSB Should I Buy - intellectia.ai
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
PDS Biotechnology Corp 2025 Annual Report: Versamune® Immunotherapy Pipeline, Clinical Results, and Executive Leadership Overview - Minichart
PDS Biotech amends phase 3 trial to speed approval timeline By Investing.com - Investing.com South Africa
PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway - Minichart
PDS Biotech (NASDAQ: PDSB) details trial progress and $26.7M cash - Stock Titan
Form 10-K PDS Biotechnology Corp For: Dec 31 - StreetInsider
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap - AlphaStreet
PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings - AlphaStreet
PDSB: Net loss narrowed, clinical trials advanced, and new patents extended exclusivity into the 2040s - TradingView
Bicara Therapeutics 2025 Financial Update - AlphaStreet
Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline - Investing.com
PDS Biotech amends phase 3 trial to speed approval timeline - Investing.com
PDS Biotechnology: Q4 Earnings Snapshot - marketscreener.com
Phase 3 trial shift and cash update for PDS Biotech (NASDAQ: PDSB) - Stock Titan
PDS Biotech Reports Full Year 2025 Financial Results and - GlobeNewswire
PDS Biotechnology FY 2025 earnings preview - MSN
PDS Biotech redesigns cancer trial to seek faster FDA approval - Stock Titan
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement - Bitget
Published on: 2026-03-28 11:50:07 - baoquankhu1.vn
Aug Breakouts: Whats the analyst consensus on PDS Biotechnology CorporationMarket Trend Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - The Manila Times
PDS Biotechnology to announce Q4 and full year results on March 30 with clinical and corporate update - Traders Union
PDS Biotech pairs 2025 results with a clinical update on March 30 - Stock Titan
Pds Biotechnology Corp Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):